SG2918
PreclinicalSmall molecule
SG2918 is one of 17 small molecule programs targeting Relapsed/Refractory Multiple Myeloma. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
20 competitors in Relapsed/refractory Multiple Myeloma
#DrugCompanyPhaseTrials
1Pomalyst
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
Decadron
AAspen Global Incorporated
Phase 3
Belamaf
GSKPhase 2
BLENREP
GGlaxo Dba Glaxosmithkline
Phase 2
Darzalex
Johnson & JohnsonPhase 1
TALVEY
Johnson & JohnsonPhase 1
Tecvayli
Johnson & JohnsonPhase 1
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 1
PD-1 Inhibitor
Johnson & JohnsonPhase 1
Etentamig
AbbViePhase 1
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SG2918. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details